Frederick Craves

Frederick Bernard Craves founded Burrill & Craves in 1994, Madrigal Pharmaceuticals, Inc. in 2000, where he worked as Lead Independent Director from 2016 to 2025, Bay City Capital LLC in 1997, where he is working as Managing Director from 2011, and Madrigal Pharmaceuticals, Inc. in 2011, where he worked as Chairman from 2011 to 2016.
Dr. Craves also founded Creative Biomolecules, Inc. Dr. Craves also currently works at Imidomics, Inc., as Chairman & Chief Executive Officer, Incyte Genomics Inc., as Director, EOS Biotechnology, Inc., as Director, Synchronicity Pharma, Inc., as Director, Tallikut Pharmaceuticals, Inc., as Director, Encarta, Inc., as Director, Bay City Capital GF Xinde Intl Life Sciences USD Fund LP, as Director, KBP Biosciences USA, Inc., as Director, Loyola Marymount University, as Trustee, and IIF Management Co. LLC, as Advisor.
Dr. Craves also formerly worked at Codon Devices, Inc., as Chairman & Chief Executive Officer, Berlex Biosciences, as President & Chief Executive Officer, Codon Corp., as Chairman & Chief Executive Officer, Berlex Laboratories, Inc., as President & Chief Executive Officer from 1990 to 1993, Epoch Biosciences, Inc., as Chairman, Reliant Pharmaceuticals LLC, as Chairman from 1999 to 2006, Poniard Pharmaceuticals, Inc., as Independent Director from 2012 to 2013, Medarex, Inc., as Director in 2009, Synta Pharmaceuticals Corp., as Director, Ion Torrent Systems, Inc., as Director, Twist Bioscience Corp., as Independent Director, Galileo Pharmaceuticals, Inc., as Director, Incyte Pharmaceuticals, Inc., as Director, BioSeek, Inc., as Director, VIA Pharmaceuticals, Inc., as Director from 2007 to 2011, GENTURAdx USA, Inc., as Director, Dermira, Inc., as Lead Independent Director, and Schering Berlin, Inc., as Executive Vice President.
Dr. Craves received his graduate degree from Wayne State University (Michigan), doctorate degree from The University of California, San Francisco, and undergraduate degree from Georgetown University.